Catalyst Pharmaceuticals, Inc. - Common Stock (CPRX)
22.56
-0.63 (-2.72%)
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for individuals with rare neurological and neuromuscular diseases
The company’s primary emphasis is on conditions like myasthenia gravis, creating targeted treatments that aim to improve patient outcomes and quality of life. Catalyst Pharmaceuticals is committed to advancing its drug pipeline through research, development, and collaboration, striving to address unmet medical needs in the rare disease landscape. With a patient-centered approach, the company aims to transform the treatment paradigm in its specialized therapeutic areas.
Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing.
